{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T02:52:32Z","timestamp":1771901552521,"version":"3.50.1"},"reference-count":53,"publisher":"Elsevier BV","issue":"50","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,2]],"date-time":"2022-11-02T00:00:00Z","timestamp":1667347200000},"content-version":"vor","delay-in-days":1,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.vaccine.2022.10.071","type":"journal-article","created":{"date-parts":[[2022,11,5]],"date-time":"2022-11-05T08:53:48Z","timestamp":1667638428000},"page":"7343-7351","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Public health impact and cost-effectiveness of implementing a \u2018pre-vaccination screening' strategy with the dengue vaccine in Puerto Rico"],"prefix":"10.1016","volume":"40","author":[{"given":"Edward","family":"Thommes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurent","family":"Coudeville","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riyadh","family":"Muhammad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Martin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher B.","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayman","family":"Chit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2022.10.071_b0005","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.vhri.2013.10.002","article-title":"Dengue epidemiology and burden of disease in Latin America and the Caribbean: a systematic review of the literature and meta-analysis","volume":"2","author":"Cafferata","year":"2013","journal-title":"Value Health Reg Issues"},{"key":"10.1016\/j.vaccine.2022.10.071_b0010","doi-asserted-by":"crossref","first-page":"8045435","DOI":"10.1155\/2017\/8045435","article-title":"Epidemiological Characteristics of Dengue Disease in Latin America and in the Caribbean: A Systematic Review of the Literature","volume":"2017","author":"Torres","year":"2017","journal-title":"J Trop Med"},{"key":"10.1016\/j.vaccine.2022.10.071_b0015","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/nature12060","article-title":"The global distribution and burden of dengue","volume":"496","author":"Bhatt","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2022.10.071_b0020","doi-asserted-by":"crossref","first-page":"3989","DOI":"10.1016\/j.vaccine.2020.04.011","article-title":"Arboviruses: A global public health threat","volume":"38","author":"Girard","year":"2020","journal-title":"Vaccine"},{"issue":"121\u201340","key":"10.1016\/j.vaccine.2022.10.071_b0025","first-page":"ix","article-title":"Dengue and dengue hemorrhagic fever in Latin America and the Caribbean","volume":"14","author":"Isturiz","year":"2000","journal-title":"Infect Dis Clin North Am"},{"key":"10.1016\/j.vaccine.2022.10.071_b0030","doi-asserted-by":"crossref","first-page":"e0005224","DOI":"10.1371\/journal.pntd.0005224","article-title":"Dengue in Latin America: Systematic Review of Molecular Epidemiological Trends","volume":"11","author":"Ramos-Castaneda","year":"2017","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2022.10.071_b0035","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1007\/s00705-013-1645-3","article-title":"Secondary infection as a risk factor for dengue hemorrhagic fever\/dengue shock syndrome: an historical perspective and role of antibody-dependent enhancement of infection","volume":"158","author":"Guzman","year":"2013","journal-title":"Arch Virol"},{"key":"10.1016\/j.vaccine.2022.10.071_b0040","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1038\/s41564-019-0476-8","article-title":"The current and future global distribution and population at risk of dengue","volume":"4","author":"Messina","year":"2019","journal-title":"Nat Microbiol"},{"key":"10.1016\/j.vaccine.2022.10.071_b0045","doi-asserted-by":"crossref","first-page":"e1752","DOI":"10.1371\/journal.pntd.0001752","article-title":"Therapeutics for dengue: recommendations for design and conduct of early-phase clinical trials","volume":"6","author":"Simmons","year":"2012","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2022.10.071_b0050","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.ijid.2016.01.015","article-title":"A comparative study on active and passive epidemiological surveillance for dengue in five countries of Latin America","volume":"44","author":"Sarti","year":"2016","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.vaccine.2022.10.071_b0055","doi-asserted-by":"crossref","first-page":"e111","DOI":"10.26633\/RPSP.2018.111","article-title":"Economic impact of dengue fever in Latin America and the Caribbean: a systematic review","volume":"42","author":"Laserna","year":"2018","journal-title":"Rev Panam Salud Publica"},{"key":"10.1016\/j.vaccine.2022.10.071_b0060","doi-asserted-by":"crossref","first-page":"200","DOI":"10.4269\/ajtmh.2011.10-0503","article-title":"Economic impact of dengue illness in the Americas","volume":"84","author":"Shepard","year":"2011","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2022.10.071_b0065","doi-asserted-by":"crossref","first-page":"e3192","DOI":"10.1371\/journal.pntd.0003192","article-title":"Physician survey to determine how dengue is diagnosed, treated and reported in Puerto Rico","volume":"8","author":"Tomashek","year":"2014","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2022.10.071_b0070","doi-asserted-by":"crossref","first-page":"e0006650","DOI":"10.1371\/journal.pntd.0006650","article-title":"Estimating dengue under-reporting in Puerto Rico using a multiplier model","volume":"12","author":"Shankar","year":"2018","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2022.10.071_b0075","doi-asserted-by":"crossref","first-page":"745","DOI":"10.4269\/ajtmh.2012.11-0784","article-title":"Economic cost of dengue in Puerto Rico","volume":"86","author":"Halasa","year":"2012","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2022.10.071_b0080","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.vaccine.2017.11.064","article-title":"Cost-effectiveness of dengue vaccination in ten endemic countries","volume":"36","author":"Zeng","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.10.071_b0085","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/1471-2334-14-38","article-title":"Ecological, biological and social dimensions of dengue vector breeding in five urban settings of Latin America: a multi-country study","volume":"14","author":"Quintero","year":"2014","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.vaccine.2022.10.071_b0090","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/S1473-3099(17)30166-4","article-title":"Safety and immunogenicity of one versus two doses of Takeda's tetravalent dengue vaccine in children in Asia and Latin America: interim results from a phase 2, randomised, placebo-controlled study","volume":"17","author":"Saez-Llorens","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2022.10.071_b0095","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1186\/1471-2458-13-607","article-title":"Sharing experiences: towards an evidence based model of dengue surveillance and outbreak response in Latin America and Asia","volume":"13","author":"Badurdeen","year":"2013","journal-title":"BMC Public Health"},{"key":"10.1016\/j.vaccine.2022.10.071_b0100","doi-asserted-by":"crossref","first-page":"e0157971","DOI":"10.1371\/journal.pone.0157971","article-title":"Alarm Variables for Dengue Outbreaks: A Multi-Centre Study in Asia and Latin America","volume":"11","author":"Bowman","year":"2016","journal-title":"PLoS ONE"},{"issue":"Suppl 1","key":"10.1016\/j.vaccine.2022.10.071_b0105","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1179\/2046904712Z.00000000046","article-title":"Dengue: an escalating public health problem in Latin America","volume":"32","author":"Tapia-Conyer","year":"2012","journal-title":"Paediatr Int Child Health"},{"key":"10.1016\/j.vaccine.2022.10.071_b0110","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciab288","article-title":"Analysis of hospitalized and severe dengue cases over the six-years of follow-up of the tetravalent dengue vaccine (CYD-TDV) efficacy trials in Asia and Latin America","author":"Forrat","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2022.10.071_b0115","doi-asserted-by":"crossref","unstructured":"Dengue vaccine: WHO position paper, September 2018 - Recommendations. Vaccine. 2019;37:4848-9.","DOI":"10.1016\/j.vaccine.2018.09.063"},{"key":"10.1016\/j.vaccine.2022.10.071_b0120","doi-asserted-by":"crossref","first-page":"6291","DOI":"10.1016\/j.vaccine.2019.09.010","article-title":"Updated recommendations of the International Dengue Initiative expert group for CYD-TDV vaccine implementation in Latin America","volume":"37","author":"Torres","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.10.071_b0125","unstructured":"Food and Drug Administration. Dengvaxia. 2020. Available from: https:\/\/www.fda.gov\/vaccines-blood-biologics\/dengvaxia (Accessed 16 May 2022)."},{"key":"10.1016\/j.vaccine.2022.10.071_b0130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr7006a1","article-title":"Dengue Vaccine: Recommendations of the Advisory Committee on Immunization Practices, United States, 2021","volume":"70","author":"Paz-Bailey","year":"2021","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.vaccine.2022.10.071_b0135","unstructured":"Department of Health. ORDEN ADMINISTRATIVA N\u00daM. 524 PARA ESTABLECER LOS CRITERIOS DE ELEGIBILIDAD PARA ADMINISTRAR LA VACUNA CONTRA EL DENGUE A PERSONAS DE 9 A 16 A\u00d1OS DE EDAD. 2021. Available from: https:\/\/www.salud.gov.pr\/CMS\/DOWNLOAD\/5848 (Accessed 10 February 2022)."},{"key":"10.1016\/j.vaccine.2022.10.071_b0140","doi-asserted-by":"crossref","first-page":"6426","DOI":"10.1016\/j.vaccine.2016.08.050","article-title":"Potential impact of dengue vaccination: Insights from two large-scale phase III trials with a tetravalent dengue vaccine","volume":"34","author":"Coudeville","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.10.071_b0145","doi-asserted-by":"crossref","first-page":"6417","DOI":"10.1016\/j.vaccine.2015.11.023","article-title":"Estimation of parameters related to vaccine efficacy and dengue transmission from two large phase III studies","volume":"34","author":"Coudeville","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.10.071_b0150","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1080\/14760584.2018.1503955","article-title":"Assessment of benefits and risks associated with dengue vaccination at the individual and population levels: a dynamic modeling approach","volume":"17","author":"Coudeville","year":"2018","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2022.10.071_b0155","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1056\/NEJMoa1800820","article-title":"Effect of Dengue Serostatus on Dengue Vaccine Safety and Efficacy","volume":"379","author":"Sridhar","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2022.10.071_b0160","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1016\/j.vaccine.2019.12.012","article-title":"The potential impact of dengue vaccination with, and without, pre-vaccination screening","volume":"38","author":"Coudeville","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.10.071_b0165","unstructured":"United Nations Department of Economic and Social Affairs PD. World Population Prospects: The 2017 Revision. 2017. Available from: https:\/\/www.un.org\/development\/desa\/publications\/world-population-prospects-the-2017-revision.html (Accessed 16 May 2022)."},{"key":"10.1016\/j.vaccine.2022.10.071_b0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.diagmicrobio.2019.114918","article-title":"Evaluation of dengue serological tests available in Puerto Rico for identification of prior dengue infection for prevaccination screening","volume":"96","author":"Bonaparte","year":"2020","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.vaccine.2022.10.071_b0175","doi-asserted-by":"crossref","DOI":"10.1093\/jtm\/taz078","article-title":"Evaluation of rapid diagnostic tests and conventional enzyme-linked immunosorbent assays to determine prior dengue infection","volume":"26","author":"Bonaparte","year":"2019","journal-title":"J Travel Med"},{"key":"10.1016\/j.vaccine.2022.10.071_b0180","unstructured":"Liberal V, Forrat R, Zhang C, Pan C, Bonaparte M, Yin W, et al. Clinical performance of a dengue IgG rapid diagnostic test designed to determine dengue serostatus as part of prevaccination screening. American Society of Hygiene and Tropical Medicine 69th Annual Meeting. Virtual Conference2020."},{"key":"10.1016\/j.vaccine.2022.10.071_b0185","unstructured":"Organisation for Economic Co-operation and Development. Prices and Purchasing Power Parities. 2022. Available from: https:\/\/www.oecd.org\/sdd\/prices-ppp\/ (Accessed 16 May 2022)."},{"key":"10.1016\/j.vaccine.2022.10.071_b0190","unstructured":"Centers for Disease Control and Prevention. CDC Vaccine Price List. 2022. Available from: https:\/\/www.cdc.gov\/vaccines\/programs\/vfc\/awardees\/vaccine-management\/price-list\/index.html (Accessed 16 May 2022)."},{"key":"10.1016\/j.vaccine.2022.10.071_b0195","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.4269\/ajtmh.18-0309","article-title":"Impact of a Nonfatal Dengue Episode on Disability-Adjusted Life Years: A Systematic Analysis","volume":"99","author":"Zeng","year":"2018","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2022.10.071_b0200","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1056\/NEJMoa1503877","article-title":"Symptomatic Dengue in Children in 10 Asian and Latin American Countries","volume":"374","author":"L'Azou","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2022.10.071_b0205","doi-asserted-by":"crossref","first-page":"874","DOI":"10.15585\/mmwr.mm6633a2","article-title":"National, Regional, State, and Selected Local Area Vaccination Coverage Among Adolescents Aged 13\u201317 Years - United States, 2016","volume":"66","author":"Walker","year":"2017","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2022.10.071_b0210","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1001\/jama.2016.12195","article-title":"Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses: Second Panel on Cost-Effectiveness in Health and Medicine","volume":"316","author":"Sanders","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2022.10.071_b0215","unstructured":"World Health Organization. Global Health Estimates: Life expectancy and leading causes of death and disability. 2019. Available from: https:\/\/www.who.int\/data\/gho\/data\/themes\/mortality-and-global-health-estimates (Accessed 18 May 2021)."},{"key":"10.1016\/j.vaccine.2022.10.071_b0220","unstructured":"World Health Organization. Cost-effectiveness thresholds. 2012. Available from: https:\/\/www.who.int\/choice\/cost-effectiveness\/en\/ (Accessed 18 May 2021)."},{"key":"10.1016\/j.vaccine.2022.10.071_b0225","unstructured":"The World Bank. DataBank: World Development Indicator. 2020. Available from: https:\/\/databank.worldbank.org\/reports.aspx?source=2&series=NY.GDP.PCAP.CD&country (Accessed 17 May 2021)."},{"key":"10.1016\/j.vaccine.2022.10.071_b0230","doi-asserted-by":"crossref","first-page":"5154","DOI":"10.1016\/j.vaccine.2020.06.028","article-title":"Economic evaluation and budget impact analysis of dengue vaccination following pre-vaccination serological screening in India","volume":"38","author":"Krishnamoorthy","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.10.071_b0235","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1017\/S0266462319000680","article-title":"Cost effectiveness of dengue vaccination following pre-vaccination serological screening in Sri Lanka","volume":"35","author":"Perera","year":"2019","journal-title":"Int J Technol Assess Health Care"},{"key":"10.1016\/j.vaccine.2022.10.071_b0240","doi-asserted-by":"crossref","first-page":"e0009606","DOI":"10.1371\/journal.pntd.0009606","article-title":"Cost-effectiveness of dengue vaccination in Puerto Rico","volume":"15","author":"Espana","year":"2021","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2022.10.071_b0245","unstructured":"Centers for Disease Control and Prevention. Laboratory Testing Requirements for Vaccination with Dengvaxia Dengue Vaccine. 2021. Available from: https:\/\/www.cdc.gov\/dengue\/vaccine\/hcp\/testing.html (Accessed 7 January 2022)"},{"key":"10.1016\/j.vaccine.2022.10.071_b0250","unstructured":"CTK Biotech. Dengue IgG Rapid Test: Instructions for use. 2021. Available from: https:\/\/drive.google.com\/file\/d\/1byo7HRdqTvq43aXEYuGV0Zf9KfI_SAME\/view (Accessed 10 February 2022)."},{"key":"10.1016\/j.vaccine.2022.10.071_b0255","unstructured":"Advisory Committe on Immunization Practices. Evaluation of commercial dengue virus igg tests for pre -vaccination screening. 2021. Available from: https:\/\/www.cdc.gov\/vaccines\/acip\/meetings\/downloads\/slides-2021-02\/24-25\/Dengue-Medina.pdf (Accessed 1 April 2022)."},{"key":"10.1016\/j.vaccine.2022.10.071_b0260","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1093\/infdis\/jiw297","article-title":"Tetravalent Dengue Vaccine Reduces Symptomatic and Asymptomatic Dengue Virus Infections in Healthy Children and Adolescents Aged 2\u201316 Years in Asia and Latin America","volume":"214","author":"Olivera-Botello","year":"2016","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2022.10.071_b0265","doi-asserted-by":"crossref","first-page":"e0005025","DOI":"10.1371\/journal.pntd.0005025","article-title":"Enhanced Surveillance for Fatal Dengue-Like Acute Febrile Illness in Puerto Rico, 2010\u20132012","volume":"10","author":"Tomashek","year":"2016","journal-title":"PLoS Negl Trop Dis"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22013433?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22013433?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:21:51Z","timestamp":1759404111000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X22013433"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":53,"journal-issue":{"issue":"50","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S0264410X22013433"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.10.071","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Public health impact and cost-effectiveness of implementing a \u2018pre-vaccination screening' strategy with the dengue vaccine in Puerto Rico","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.10.071","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}